Literature DB >> 11056103

Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta.

M O Hiltunen1, M Laitinen, M P Turunen, M Jeltsch, J Hartikainen, T T Rissanen, J Laukkanen, M Niemi, M Kossila, T P Häkkinen, A Kivelä, B Enholm, H Mansukoski, A M Turunen, K Alitalo, S Ylä-Herttuala.   

Abstract

BACKGROUND: Gene transfer to the vessel wall may provide new possibilities for the treatment of vascular disorders, such as postangioplasty restenosis. In this study, we analyzed the effects of adenovirus-mediated vascular endothelial growth factor (VEGF)-C gene transfer on neointima formation after endothelial denudation in rabbits. For comparison, a second group was treated with VEGF-A adenovirus and a third group with lacZ adenovirus. Clinical-grade adenoviruses were used for the study. METHODS AND
RESULTS: Aortas of cholesterol-fed New Zealand White rabbits were balloon-denuded, and gene transfer was performed 3 days later. Animals were euthanized 2 and 4 weeks after the gene transfer, and intima/media ratio (I/M), histology, and cell proliferation were analyzed. Two weeks after the gene transfer, I/M in the lacZ-transfected control group was 0. 57+/-0.04. VEGF-C gene transfer reduced I/M to 0.38+/-0.02 (P:<0.05 versus lacZ group). I/M in VEGF-A-treated animals was 0.49+/-0.17 (P:=NS). The tendency that both VEGF groups had smaller I/M persisted at the 4-week time point, when the lacZ group had an I/M of 0.73+/-0.16, the VEGF-C group 0.44+/-0.14, and the VEGF-A group 0. 63+/-0.21 (P:=NS). Expression of VEGF receptors 1, 2, and 3 was detected in the vessel wall by immunocytochemistry and in situ hybridization. As an additional control, the effect of adenovirus on cell proliferation was analyzed by performing gene transfer to intact aorta without endothelial denudation. No differences were seen in smooth muscle cell proliferation or I/M between lacZ adenovirus and 0.9% saline-treated animals.
CONCLUSIONS: Adenovirus-mediated VEGF-C gene transfer may be useful for the treatment of postangioplasty restenosis and vessel wall thickening after vascular manipulations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11056103     DOI: 10.1161/01.cir.102.18.2262

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

Review 1.  Clinical applications of vascular gene therapy.

Authors:  J Rutanen; T T Rissanen; A Kivelä; I Vajanto; S Ylä-Herttuala
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

2.  Inhibition of intimal hyperplasia via local delivery of vascular endothelial growth factor cDNA nanoparticles in a rabbit model of restenosis induced by abdominal aorta balloon injury.

Authors:  Hongzhi Xie; Jing Yang; Yechen Han; Xueqing Zhu; Quan Fang
Journal:  Exp Ther Med       Date:  2015-04-21       Impact factor: 2.447

3.  A model for gene therapy of human hereditary lymphedema.

Authors:  M J Karkkainen; A Saaristo; L Jussila; K A Karila; E C Lawrence; K Pajusola; H Bueler; A Eichmann; R Kauppinen; M I Kettunen; S Yla-Herttuala; D N Finegold; R E Ferrell; K Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

Review 4.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

5.  Effects of local gene transfer of VEGF on neointima formation after balloon injury in hypercholesterolemic rabbits.

Authors:  Jozef Dulak; Severin P Schwarzacher; Ralf H Zwick; Hannes Alber; Gunda Millonig; Caecilia Weiss; Heike Hügel; Matthias Frick; Alicja Jozkowicz; Otmar Pachinger; Franz Weidinger
Journal:  Vasc Med       Date:  2005-11       Impact factor: 3.239

6.  Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration.

Authors:  Tuomas T Rissanen; Ismo Vajanto; Mikko O Hiltunen; Juha Rutanen; Mikko I Kettunen; Mari Niemi; Pia Leppänen; Mikko P Turunen; Johanna E Markkanen; Katja Arve; Esko Alhava; Risto A Kauppinen; Seppo Ylä-Herttuala
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 7.  Neointimal hyperplasia associated with synthetic hemodialysis grafts.

Authors:  Li Li; Christi M Terry; Yan-Ting E Shiu; Alfred K Cheung
Journal:  Kidney Int       Date:  2008-07-30       Impact factor: 10.612

Review 8.  Gene therapy for restenosis: current status.

Authors:  Juha Rutanen; Johanna Markkanen; Seppo Ylä-Herttuala
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis.

Authors:  Timmy Lee; Prabir Roy-Chaudhury
Journal:  Adv Chronic Kidney Dis       Date:  2009-09       Impact factor: 3.620

10.  CD133 antibody conjugation to decellularized human heart valves intended for circulating cell capture.

Authors:  John D Vossler; Young Min Ju; J Koudy Williams; Steven Goldstein; James Hamlin; Sang Jin Lee; James J Yoo; Anthony Atala
Journal:  Biomed Mater       Date:  2015-09-03       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.